HTRS2025.P2.64 Reduced Doses of Factor Concentrates and Bypassing Agents to Treat Breakthrough Bleeds in Patients with Hemophilia A or B on Fitusiran Antithrombin-Based Dosing Regimen (AT-DR): ATLAS-OLE

Documenti analoghi

• HTRS2025.P2.64 Reduced Doses of Factor Concentrates and Bypassing Agents to Treat Breakthrough Bleeds in Patients with Hemophilia A or B on Fitusiran Antithrombin-Based Dosing Regimen (AT-DR): ATLAS-OLE
  di: Amy Chen, et al.
  Pubblicazione: (2025-11-01)
• SURGICAL EXPERIENCE IN PEOPLE WITH HEMOPHILIA A OR B WITH AND WITHOUT INHIBITORS RECEIVING FITUSIRAN
  di: Alok-Srivastava, et al.
  Pubblicazione: (2024-10-01)
• S301: CONSUMPTION OF FACTOR CONCENTRATES AND BYPASSING AGENTS FOR MANAGEMENT OF BREAKTHROUGH BLEEDS WITH FITUSIRAN PROPHYLAXIS IN PEOPLE WITH HAEMOPHILIA A OR B: ANALYSIS OF ATLAS-PPX
  di: Gili Kenet, et al.
  Pubblicazione: (2023-08-01)
• Analytical validity of the INNOVANCE Antithrombin assay for the measurement of antithrombin activity at fitusiran clinical decision points
  di: Christoph Freidel, et al.
  Pubblicazione: (2026-03-01)
• HTRS2025.P1.22 Orthopedic and dental surgeries conducted under fitusiran prophylaxis in people with hemophilia A or B with or without inhibitors
  di: Larissa Bornikova, et al.
  Pubblicazione: (2025-11-01)